GlassScriptPhysician profile
Rajat Daniel
NPI 1336203603
$1,987.47
in general payments reported to CMS, 2019-2025
20 companies · $770 in 2025
The $770 reported for 2025 was more than what 81% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $141 · 2020: $135 · 2021: $210 · 2022: $323 · 2023: $92.98 · 2024: $317 · 2025: $770.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,179.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,179.30 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $577.66 | 2019-2025 | Zepbound, Jardiance, Mounjaro |
| Abbvie INC. | $283.20 | 2021-2025 | Vraylar |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $273.15 | 2024-2025 | Caplyta |
| Astrazeneca Pharmaceuticals LP | $190.69 | 2019-2025 | Airsupra, Breztri |
| Otsuka America Pharmaceutical, INC. | $130.13 | 2024-2025 | Rexulti |
| Allergan, INC. | $77.30 | 2020 | |
| Vanda Pharmaceuticals INC. | $75.08 | 2025 | Fanapt |
| Kowa Pharmaceuticals America, INC. | $53.96 | 2022-2023 | Seglentis |
| Dexcom, INC. | $51.88 | 2021-2022 | |
| Pfizer INC. | $39.90 | 2025 | |
| Amgen INC. | $36.42 | 2022-2024 | Repatha, Otezla |
| Axsome Therapeutics, INC. | $35.29 | 2024 | Auvelity |
| Teva Pharmaceuticals USA, INC. | $26.53 | 2024 | Ajovy |
| Phathom Pharmaceuticals, INC. | $22.44 | 2025 | Voquezna |
| Astellas Pharma US INC | $21.28 | 2025 | Veozah |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $21.17 | 2024 | Wegovy |
| Biohaven Pharmaceutical Holding Company LTD. | $20.97 | 2022 | |
| Actelion Pharmaceuticals US, INC. | $18.29 | 2025 | Opsumit, Uptravi |
| Bayer Healthcare Pharmaceuticals INC. | $16.57 | 2023 | |
| Glaxosmithkline, LLC. | $15.56 | 2025 | Trelegy Ellipta |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rajat Daniel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.